Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Market Size Estimates For The Anti-Cancer MAbS Market?

The market for anti-cancer MAbS has witnessed robust growth in the past years. It is projected to expand from $65.35 billion in 2024 to $71.25 billion in 2025, representing a compound annual growth rate (CAGR) of 9.0%. Factors such as heightened occurrence of cancer, better understanding of cancer biology, a shift towards personalized medicine, increased R&D investment, and an increase in patient awareness and demand have contributed to the historical growth trajectory.

A strong upsurge in growth is anticipated in the anti-cancer MAbS market size over the coming years. It is projected to expand to “$102.74 billion by 2029, with a compound annual growth rate (CAGR) of 9.6%. The improvements in immunotherapy, increased use of combination therapies, emergence of next-generation mAbs, global initiatives to tackle the cancer burden, and the enlargement of patient access programs are the contributing factors for the growth in the forecast period. The upcoming period is also expected to witness trends such as advancements in drug delivery technologies, use of artificial intelligence in drug discovery, collaborations and partnerships within the pharmaceutical sector, biotech innovations, and car-t cell therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp

What Core Drivers Are Expected To Influence The Anti-Cancer MAbS Market?

The rising incidence of cancer worldwide is set to drive the growth of the anticancer MABs market. Cancer is a long-lasting, chronic disease. Anticancer monoclonal antibodies (mAbs) are uniquely crafted to attach to specific proteins present on cancer cells and utilise genetically modified versions of the body’s own antibodies to target and eliminate these cancer cells. Therefore, the higher the incidence of cancer, the greater the demand for anticancer MABs. As reported by PubMed, a biomedical and life sciences journal based in the US, in January 2022, an estimated 1.9 million new cancer diagnoses are expected globally, with cancer expected to claim 609,360 lives in the United States alone. Hence, the rising occurrence of cancer throughout the world is fuelling the growth of the anticancer mAbs market.

How Is The Anti-Cancer MAbS Market Organized By Different Segments?

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

Subsegments:

1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes

2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes

3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes

4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats

What Current And Upcoming Trends Are Shaping The Anti-Cancer MAbS Market?

In the anticancer mAbs market, a prominent trend is the rise of product innovations. To consolidate their market presence, major firms are unveiling more effective and precise cancer therapies, such as mAbs drugs. For example, in May 2022, Roche Holding AG, a pharmaceutical powerhouse based in Switzerland, debuted PHESGO. Specific to treating HER2-positive early breast cancer, PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) stands as a unique monoclonal antibody (mAb) blend treatment. Instead of being administered intravenously, this combination of two mAbs, pertuzumab and trastuzumab, and hyaluronidase—an enzyme that facilitates greater mAb absorption—is delivered subcutaneously.

Who Are The Most Influential Companies In The Anti-Cancer MAbS Market?

Major companies operating in the anti-cancer mabs market include Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Which Region Dominates The Anti-Cancer MAbS Market Today?

North America was the largest region in the anti-cancer MAbS market in 2024. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9041&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model